Bristol-Myers Squibb announces executive changes
NEW YORK — Bristol-Myers Squibb announced changes to its senior management team, including the appointment of its U.S. pharmaceuticals president.
The drug maker said SVP oncology and immunology global commercialization Giovanni Caforio has been promoted to president of U.S. pharmaceuticals. Additionally, Bristol named Charles Bancroft and Béatrice Cazala as EVPs. Bancroft will add to his role of CFO operational responsibility for the pharmaceutical business in Latin America, Middle East, Africa, Canada, Japan and several other countries in the Pacific Rim. Meanwhile, Cazala will add responsibility for global policy to her role leading global commercialization, Europe and emerging markets.
In related news, Anthony Hooper, SVP commercial operations and president of U.S., Japan and intercontinental, has decided to leave the company. He has joined Amgen as EVP global commercial operations.
All of the executives will report to Bristol CEO Lamberto Andreotti.
“A focus on developing talent at all levels is a key element of our Bristol-Myers Squibb culture,” Andreotti said. “I am excited to expand the roles of Giovanni, Charlie and Béatrice, and look forward to working with these three senior leaders and the rest of my management team to continue to successfully execute our BioPharma strategy.”
FRS appoints chief marketing officer
FOSTER CITY, Calif. — The FRS Co. on Thursday named Matt Kohler chief marketing officer.
"Matt has a deep understanding of consumers and the CPG industry and an impressive track record for creating and executing world class marketing," stated Carl Sweat, president and CEO of the FRS Co. "We are thrilled to have Matt on board. His experience with both billion dollar brands and high-growth startup companies will enhance the strength of our marketing and leadership teams."
In his new position, Kohler will oversee global marketing efforts including brand strategy, product innovation, advertising, promotions, social media and event marketing. Kohler will report directly to Sweat.
"This is an exciting time to join FRS. The company’s FRS Healthy Performance line of products is strongly positioned for growth," Kohler said.
Prior to joining FRS, Kohler served as VP marketing at Green Dot Corp., a provider of financial services. Kohler led all marketing activities for the Green Dot brand from its entrepreneurial growth stage through a successful IPO.
Previously, Kohler worked in brand management at The Clorox Company, where he was responsible for the company’s bleach brand. There, Kohler successfully launched Green Works, an innovative line of "green" plant-based cleansers, from concept to commercialization and the first new brand launch for Clorox in more than 20 years. Kohler has worked nationally and internationally for such leading brands as Coca-Cola and Johnson & Johnson. Kohler received an MBA from Harvard and a BA from American University.
GPhA to Senate: Fully funded FDA will benefit healthcare system, expand patient access to affordable drugs
WASHINGTON — It is critical for the Food and Drug Administration and Office of Generic Drugs to be fully funded so that patients can receive access to affordable medicines, the Generic Pharmaceutical Association said Wednesday.
The group called on the Senate to uphold the funds allocated to the FDA by the Senate Committee on Appropriations. GPhA president and CEO Ralph Neas said that cutting funds would affect the sustainability of the U.S. healthcare system, including such programs as Medicare and Medicaid.
“At a time when lawmakers in Washington and across the country are under enormous pressure to cut budgets and reduce spending, we applaud the committee’s foresight in recognizing the importance of a fully funded FDA," Neas said. "Today, the use of safe and effective generic prescription drugs is saving consumers and the U.S. healthcare system more than $3 billion every week. It is absolutely critical that the Senate provide the FDA with the appropriate funding to ensure that patients continue to have access to these medicines at a price they can afford.”